Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jun;106 Suppl 3(Suppl 3):813-6.
doi: 10.1289/ehp.98106813.

Biomarkers in pediatric environmental health: a cross-cutting issue

Affiliations

Biomarkers in pediatric environmental health: a cross-cutting issue

C F Bearer. Environ Health Perspect. 1998 Jun.

Abstract

It is not yet known the extent to which the environment adversely affects the health of the developing individual. Difficulties in this determination are the problems of a) the assessment of exposure, b) the long latency of many diseases induced by the environment, c) the number of confounding exposures, and d) the extrapolation of animal models to critical stages of human development. Biomarkers have the potential to be quantitative dosimeters of exposure and biologic effective dose, as well as early warning signals of biologic effect. Biomarkers may document interindividual susceptibilities, as well as defining critical windows of exposure. To be useful, biomarkers need to be validated in terms of their specificity and sensitivity. Biomarkers are useful across all disciplines including asthma and respiratory problems, developmental neurotoxicity, childhood cancer, and endocrine disruptors. Biomarkers have not been developed nor used widely in pediatric environmental health. Research by our group and others has documented the validity of biomarkers in pediatric environmental health. Advances in the field of biomarkers may have important implications for the detection, prevention, and treatment of environmentally induced diseases in children. Ongoing validation of promising biomarkers should be a research priority.

PubMed Disclaimer

References

    1. Clin Perinatol. 1986 Sep;13(3):545-54 - PubMed
    1. N Engl J Med. 1987 Apr 23;316(17):1037-43 - PubMed
    1. N Engl J Med. 1990 May 31;322(22):1567-72 - PubMed
    1. N Engl J Med. 1991 Apr 25;324(17):1168-73 - PubMed
    1. N Engl J Med. 1992 Jan 9;326(2):137 - PubMed

Publication types